Results 111 to 120 of about 225,851 (312)

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

open access: yesMolecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena   +15 more
wiley   +1 more source

Technological innovations redefining the insurance landscape: A technical analysis

open access: yesWorld Journal of Advanced Research and Reviews
The insurance industry is undergoing a profound technological transformation, shifting from traditional paper-based processes toward digital innovation. This article explores how cutting-edge technologies—artificial intelligence, machine learning, Internet of Things, blockchain, and cloud computing—are revolutionizing the insurance landscape.
openaire   +1 more source

Systematized and Path-independent Measurement of Biased Technical Change [PDF]

open access: yes
The sample-specificity and path-dependence of the data envelopment analysis (DEA) based technical change index as a component of Malmquist indexes prevent us from obtaining overall and systematic information on technical change.
Tsunehiro Otsuki
core  

Interpreting the effects of DNA polymerase variants at the structural level

open access: yesMolecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi   +7 more
wiley   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

STUDIES AND RESEARCH ON DESIGN OF EFFICIENCY TECHNOLOGICAL PROCESSES BY ESTIMATING THE RISKS [PDF]

open access: yesAnnals: Series on engineering sciences (Academy of Romanian Scientists), 2015
In order to identify sources of risk, the project manager will have to define the type of project which is the subject analysis which can offer options and especially sources of analysis of the specific risk factors.
Alina-Elena BUȘARU   +4 more
doaj  

Consolidation, Scale Economics and Technological Change in Japanese Banking [PDF]

open access: yes
The paper examines the technological structure of the Japanese banking sector before the onset of the banking crisis and structural reforms of the 90s in order to shade light on the logic of the recent trend to consolidation in the industry.
Solomon Tadesse
core  

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

open access: yesMolecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel   +12 more
wiley   +1 more source

Socio-technical transition pathways and social networks: a toolkit for empirical innovation studies [PDF]

open access: yes
In this note we investigate socio-technical transition pathways concentrating our attention on innovation niches formations. Specifically, we present a methodological conceptualization of innovation-niches and propose a preliminary protocol, based on a ...
Piergiuseppe Morone, Antonio Lopolito
core  

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy